CA2236807A1 - Reconstituted mineralized cartilage tissue - Google Patents

Reconstituted mineralized cartilage tissue Download PDF

Info

Publication number
CA2236807A1
CA2236807A1 CA002236807A CA2236807A CA2236807A1 CA 2236807 A1 CA2236807 A1 CA 2236807A1 CA 002236807 A CA002236807 A CA 002236807A CA 2236807 A CA2236807 A CA 2236807A CA 2236807 A1 CA2236807 A1 CA 2236807A1
Authority
CA
Canada
Prior art keywords
cartilage
biological material
chondrocytes
tissue
mineralized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002236807A
Other languages
French (fr)
Inventor
Rita Kandel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mount Sinai Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2236807A1 publication Critical patent/CA2236807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817Cartilage-forming cells, e.g. pre-chondrocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3612Cartilage, synovial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633Extracellular matrix [ECM]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645Connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645Connective tissue
    • A61L27/365Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3695Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843Connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843Connective tissue
    • A61L27/3847Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068General culture methods using substrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655Chondrocytes; Cartilage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/06Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/42Organic phosphate, e.g. beta glycerophosphate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/90Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/915Method or apparatus for preparing biological material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/915Method or apparatus for preparing biological material
    • Y10S623/919Bone

Abstract

A biological material comprising a continuous layer of cartilaginous tissue reconstituted in vitro which contains components associated with cartilage mineralization. The biological material may be cultured with a mineralizing agent to form a mineralized biological material. The mineralized biological material is characterized by having a biochemical composition and physiological organization substantially similar to the deep and contiguous calcified cartilage zones of articular cartilage found in animals in vivo.
Methods for preparing the biological materials and methods of using the biological materials are described.

Description

CA 02236807 l998-05-04 W O 97/17430 PCT/CA9G~ 7 9 Title: pc~cor~lsl l lUl~ ) MIr~RAT-~7,~n CARTILAG~ TISSU13 Flli,l ,1~ OF Tl~ ~: INVF l~TION
The present invention relates to a biologir~l m~t~ri~l ~nrirhr.d for co... ~ .. r.. lY of mine.~lli~d cat~ilage tissue; a min.~rAli7~d biological m~t~-ri~l m~!thorlc for producing the biological m ~t~ri ~1 c; and m.othr~le of using the binlogir~l m ~t~.ri ~1 c RA(~KG~OUND OF TFF Il~ TION
Articular car~ilage is a spe( i~li7çd tissue found at the end of artiC~ tin~ bones. It is .~ '';bl~ for the ~lietrihllti~ n of load reCict~nre to cu .. ~r~,v~ forces, and the smooth glidtng that is patt of joint fimrtinn AIticular cartilage is joined to its underlying stlbrhnntlrf~l bone by a zone of c~t~ifi~l ç~rlila~ The ç~leifiçd cartilage zone is involved in the distribution of force across the joint. The c~lrified zone foIms after secnn~l~ry occifir,~ti~n and acts like a growTh plate during ",;.~ n (Oegto~n~ Jr. TR and Thrmrson RC in Articular Carlilage and O~Lo~ ~iLis ed. Kn.o,t~n~.r K. et al., pp. 319-331, 1992). Its thir~n~cc is in paTt a fimrfi~n of weight bearing ae Muller-Gerbl et al. (J. Anat. 154:103, 1987) have shown. In that study they d~monYtrated that the ~c ~ , of cartilage cn~;Y~ g of c~lrifiçd caTtilage is c~ and vaTies between individuals between 3 to 8.8% ofthe car~lage thir~necc (Quarto et al. J Cell Biol 110:1379. 1990)-2 0 Litlle is known aboutthe c-,.~ ~~ n of the c~Wfi~d cartilage and the mrt~holicm of cL~,.. d-~,~t~,s within and ;.. ~ ly above the cAlrified caTtilage zone. In vivo, the cells in this region have alkaline phnsrh~t~ce activity. While the major c~ g~.n is type II, type X
cc~ g~-n is also present. CaTtilage in the c~l rifird zone cc . . ~ ~-; . .c about half the proteoglycans found withinmature aTticular car~lage deep zones. Rcie~.,hc,.:. have also lG~ulLl the lJ-~,;,.".~C
2 5 of o~t " .r.,l; " as well as a unique protein seen only in the c~lrifi~d zone. The mineral present in the c~lnified zone varies between species, but shows the cha.~t~ l;r 1.67 calcium-to-.l~n~l.hh l ~ ratio of Ly~Lu~ya~ (Oegema et al. in Articular CaTtilage and O~h,o~ lll-iLis, ed.
Knettn~!r K. et aL pp. 319, 1992). The process of c~lrifir,~tinn has been found to be very-c ,'.t involving-l;rf.-~-l ;..l .,,~I;..gmatrix mnl- leS andcarefulreg~ fil~natthecellular 3 0 level t_rough a _ , 1 multi~ .. 1.. I system which involves many cellular, hnrml)n~l and ~Ly~ ro~l-/ ...ir~l l...,cc;,ses (Poole et al. Anat. Rec. 224:167, 1989).
FY1~ 1 studies have sn,~gested that the cS~lrifiçd cartilage plays a role in thepathogenesis of the joint disease oa~ci~ll~ilis. ~mstl~lling of the c~lrified cartilage with rednrliri~tinn of the tirl~ m ' (the ;--t- ~ r~- c between thc c~lrifi~d and non-c~lrified cartilage) is ch~ l;r, of o;,t~,oA-~ ;c (Hough AJ et al., in Arthritis and Allied Cnnrlitinnc~ ed SUBSTITUTE SHEET (RULE 21i) WO 97/17430 PCT/CA~6/'~29 McCarty DJ pp. 1571, 1989). It has been postnl~ted that is possible that changes at the osteoarticular junction may contribute to the development of osteoarthritis. In support of this concept Thomrsnn et al. (J. Bone Surg. 73A:990, 1991), using an acute transarticular damage dog model, observed that the dogs develop cartilage degeneration over time if the c~lcified cartilage and sllbrhonrlrAl bone are rlAmA~l This may be relevant to the pathogenesis of osteoa. Ll. . iLis in humans as MRI studies have shown that up to 72% of individuals, who injure theirjoints, will have snhrhon.1r~.1 r. a~.L~u~,s without cartilage damage (Vellet et al., Radiology-178:271, 1991).
Metabolic changes have been i~lP.ntified in osteoarthritis cartilage that suggest 1 0 involvement of the deep and/or calcified cartilage in this disease. Increased numbers of matrix vesicles and matrix vesicle AccoriAted ~ y~es occur in osteoarthritic cartilage (Ali, S.Y. et al.
Fed. Proc. 32: 1494-1498, 1971; L~ ..L~ , R et al., Acta. Orthop. Scand. 52:684, 1981; and, F.inhom TA et al, J. Orthop Research 3:160, 1985). In addition, chonJ~u~iyt~,i, isolated from osteoarthritic cartilage show increased synthesis of ty-pe X collagen (Walker et al. J. Orthop Research 13:4, 1995).
Study of the calcified cartilage zane has been hampered, in part, by the lack of an in vi~ro culture system. Although many types of in vitro .~ li,;"g chondrocyte culture systems have been ~lesrrihe~l these cultures use either growth plate chondlu.,yL~s (Okihana H et al., Hi~ h~ ;rAl J25:166, 1993;Nal~a~waetal.~ Calcif. Tissue Int. 53:127, 1993; Kato Y., etal., 2 0 Proc. Natl. Acad. Sci. USA 85: 9552, 1988), embryonic chondrocytes, or e.llbly(JIlic growth plate chon~LucyLt;s~ cells whose fimctit-n in vivo is to form bone (Glaser JH et al., Journal of Bi~-lngir~l ~'hPmi~t~y,256: 12607, 1981; C~ ..rekl LC et al., Journal of Cell Biology, 112:501, 1993; Hascall VC et al., Journal of Biologic ~ h~ mi~try, 251 :3511, 1976; Bluchl~ P et al., Journal of Cell Biology, 109:2537, 1989). The tissue formed by these cells is not well suited 2 5 to the study of articular cartilage mineralization as the cartilage serves as a temrlAte for bone r~.. ~1;.. ~ The cells in the ~i~Ly:~dl plate cartilage go through a series of cytological changes as they progress through to cAlrifir~tion In ~ 1itinn, they are surrounded by small amounts of matrix which will be ~ d by vascular r.h~nnPlc (Poole et al. Anat. Rec. 224: 167, 1989).
In contrast, the cAlcified zone of adult cartilage appears to be hyaline cartilage that undergoes 3 o minerAli~ASion and does not usually undergo vascular invasion unless there is an underlying disease process. Therefore, it is not a~J~lUI;llid~ to e~lla~oldt~ observations ~ ated from these mineralizing cultures to the calcified articular cartilage.
U.S. Patent Serial No. 5,326,357 to the present hlv~lltol, describes a rec-n~titntPd cartilage tissue ch~u~cl~.. ;,. d by a c~.. li.. us layer of cartilage tissue having a ~ b:j~ .. I;A1 extracellular mat~ix and po~ ;. .g zones similar to those found in animal cartilage in vivo, and methods for ~ ~ing the rtiCo~ d cartilage tissue.
SUM~IARY OF THE INVENTION
The present inventor has ~ d an in vitro culture system which mimics the deep articular cartilage and A~lja~nt calcified cartilage zone of articular cartilage. The cultured mineralized cartilaginous tissue c-...l7.;..c calcium apatite mineral, matrix vesicles, Type X
collagen and it has alkaline phc sphAta~e activity. Polydisperse proteoglycans are srth.o.~i7Pd by the chondrocytes in the mineralized cartilage tissue. The proteoglycans have a larger hydludylldlluc size than the proteoglycans ~y~ d by articular chon~llu~;yLes in recr~n~titllted non-mineralized cartilage in culture.
Broadly stated the mvention relates to a binlogirAl material c~mrri~ing a layer of cartilaginous tissue l~,CO~ in vitro which cnntain~ cc)~ unc~L~ ~esociAt~d with cartilage minerAli7Afinn The invention also broadly c~"-l- .,.l~lAf~s a mineralized biological material charact~ri7~d by having a biochP.nnicAl composition and physiological orgAni7Ation :,ul,sLd,lLially similar to the deep and cnnti~lonC calcified cartilage zones of articular cartilage foumd in animals in vivo.
Chon.l.ù~yLes from the mid and superficial zones of articular cartilage tissue may be cultured on top of the biological material of the invention to produce a recnnctihlt~cl mineralized cartilAginc~ tissue which cnmrri~es the mineralized biological mAtlorial of the 2 O imvention; and amid and sn~ rfiriAl non-mineralized layer adjacent to and contiguous with the mineralized biological mAt.~rial The snr~.rfiriAl and mid non-minerali7ed layers have a hio. .h~ ;Al cunl~ o:,iLion and physiological ul~" ~I; ,,.I;nn similar to the mid and snr~rficiAl zones .,spe~,Liv~ly, of articular cartilage found in animals in vivo. Therefore, the recnn~titl~ted mineralized cartilage tissue is s~,l,s~ ~..1 ;Ally similar to articular cartilage tissue in vivo.
The invention also relates to a process for producing the biological mAt~ri~l of the invention c~ mrri~in~ lAting chonLu~,ytes from the deep zone of cartilage tissue; forming a layer of the chondrocytes on a substrate, and; c.-ltllring the chondrocytes in growth media under suitable ctm~lition~ so that the chondrocytes accnm-.lAte matrix and form cartilAginolls tissue which is enriched with components associated with cartilage minerali7Ati~ n ~ 3 0 The process may A~lrliti~nAlly comprise the steps of culturing the chondrocytes or cartilaginous tissue in the presence of a mineralizing agent, to form a CO~luuuS layer of a ~ mineralized biological material charactrri7~d by having a bior.hPmi~l composition and physiological or~Ani7~tinn ~ ;ally similar to the deep and contiguous calcified cartilage zones of articular car~lage found in animals in vivo.

In the alL il uaLi~ ~" the process of the inven*on may optionally cnmpriee the steps of cnltnring chondrocytes isolated from the mid and snr~orfici~l zones of articular cartilaginous tissue on top of the car~ ginnll~ tissue in the lul~encc of a mineralizing agent to produce a recon~tit~-ted mineralized cartilage *ssue which has a deep min~r~li7rd layer, and mid and superficial non-mincl~li~d layers.
The invention further relates to a mineralized biological m~ff-.ri~l compri~ing a continuous layer of min~.rAli7rd cartil~ginr..~ *issue having a biorhemic .l composi*on and physiological ul~ ;on ~..h ~In~ lly sirnilarto the deep and crn*f~lous c~lcifi~d cartilage zones of articular cartilage found in animals in vivo, obt~in~d by (a) i~ola*ng chon&u~;yL~s from the deep zone of articular cartilage tissue; forming a layer of the chondrocytes on a sul~sLI~Le, and (b)(i) cnlt..ring the chondlu~yh s in growth media under suitable con-li*on~ so that the chondrocytes ac cnm-ll~te matrix and form cartilaginous tissue, and c~.ltl-ring the cartilaginous *ssueinthe~ lceofa...;.~ l;,;..gagent,or(ii)culturingthechondrocytesingrowthmedia in the ~U~ ,..Cc of a mineralizing agent.
The chondrocytes in the biological m~t-ori~lc or rec~n~t*t~ted minerali_ed c~rtil~gin~ ~lc tissue may be l . ,.. ~rl .. ~d with . ~ .. l .i~ vectors c~ l n; .. ; .~g an r~og~nous gene rnro~lin~ a biologically ac*ve protein which corrects or cùlllpellsdLes for a gene*c ~l.ofirit-nry Therefore, the invention also c.)..l. -..pl~tPs a mineralized biological m~f~-ri~l or l~.c.~
mine}alized cartil~ginn..~ tissue wherein chondrocytes in the mineralized biological material or recon~tit--t~d mineralized cartilaginous tissue are tran~form~d with recombinant vectors c.~.~ln;..;..,~ an exogenous gene encoding a biologicaUy active protein which corrects or cnmpt~n~tr~ for a gene*c deficiency.
The invention still further relates to a system for testing a s -hst~nre that affects c~ fir.~ti- n of ar*cular cartilage *ssue c~ g culturing a biological m~t~ri~l, mineralized biological m~trriiql or recrn~titut~od mineralized cartilaginous *ssue of the invention in the presence of a s..l~ re which is ~ c~lrd of ~ffec~in~ c~lcifica*-n and del~ g the hiorh~mirzll cc ulposiLion and/or physiological Ol ~i" .i7.-~ ;on of tissue generated in the culture, with the hiorhrmir~l ccl-l~,u~ ion and/or phyqinlogir~l Ol~ n of tne biological m~tto.riz-l minPrzlli7~d h;~k~ir~l m~t~n~1, omc;~ d mineralized cartilaginous tissue cultured in the 3 0 absence of the ~i. .h:,l ,.. .~c The :,. .h:jl A.~ C may be added to the culture, or the chondrocytes in the biological m~tPri~lc or l~c-~ d mineralized cartilaginous tissue may be geneticaUy rn~ ,d to express the snhst~nre i.e. the chondrocytes may serve as an endogenous source of the s--hst~nre.
The invention stiU further relates to a method of using the biological m~trri~l~ and 3 5 l~,C~ d mineralized cartilage tissue of the invention to test rh~rm ~rentir~l ~Ul~ Lions for efficacy in the lltial~ t of diseases of the joint and to a method of using the biological ms~terisl1,c and ~t;c.. ~ d mineralized cartilaginous tissue of the present invention as an implant to replace or repair rlslmz~ed or deficient cartilage. The invention also c~ 1s~t~os using the biological ms~t~ristl.c ofthe invention in gene therapy.
The invention also c~ c a method of replacing or repairing flstmztged or t1~firi~ntcaltilagemajomtofapatientc~ ;c;~gimplantingamineralizedbiologicalmateria or reconctitnt.o.d mineralized cartilaginous tissue of the invention in the joint of the patient.
Methods for t nhs nring healing of a bone fracture in a patient are c~ .lated which comprise inserting a mineralized biological material or recnn,C,tit 1tecl minor~1i7od cartilaginous tissue of the invention into the site of a fracture.
These and other acpects ofthe present invention will become evident upon ~ ce to the following detailed description and attached drawings.
Dl~ IPTION OF THE DRAWINGS
The invention will be better nnt1pnctnod with reference to the drawings in which:
Figure lA is a photomicrograph showing the histological ~pca~ ce of fnrmsl1in fixed and paraffin embedded chondrocyte cultures harvested at two weeks;
Figure lB is a photomicrograph showing the histological appearance of fnrmsl1in fixed and paraf~n ~ he~ d chondrocyte cultures which had been grown in the ~ ;stincc of ~-~ly~ lul.ho.crhStte (lOmM) and harvested after eight weeks of culture;
Figure 2 is a graph showing alkaline phosrhstsce activity of cultures of deep chon~,.,y~t~s immediately prior to and during matlix minerstli7sttinn, Figure 3A is an electron micrograph of cartilaginous tissue showing chondrocytes(C) and mineral deposits in the extrStr.-.1h-1S~r matrix (<) (lead citrate and uranyl acetate, mst~nificsttion x 20,000);
Figure 3B is an electron micrograph of mineral deposits and matrix vesicles (mstgnifirsttit n x l l,OOO); and Figure 3C is an electron diffraction pattern of cry-stals which is chstrslct~.rietir of hytll~ya,~al.iLe.
Figure 4A is an autoradiogram of pepsin t~ ..,~d [14C~ proline labelled collagens 3 0 synth~ei7~1 by chulld-~.;yl~s after fnrrnsttinn of the car~i1stginm-c tissue (14 days) and when the tissue was mineralized (28 days);
Figure 4B is an immunoblot showing an analysis of collagens extracted from d cultures (day 28) using antibodies reactive with ty-pe II collagen (II), type I collagen (I), or t-ype X cn11stgen (X);

Figure 4C is a proteoglycan elution profile of newly synth~i7ed proteoglycans e..~ .;1 from 6 week old ...;..- .ali~rd cartilaginous tissue formed in culture (---); and 7 week old non-mineralized cartil~ginm.~ tissue formed in culture (o-o).
Figure 5 is a photomicrograph of a fnrmAlin fixed, paraffin ~-.mherlfl~d 49 day old culture showing ~ ' r,.. :~l and mitl7.one chondrocytes cultured on tissue formed by deep cells;
and Figure6isa~ n..~ u~alhshowingthehictr~lngir~Ala~ .rcoff~TTnAlin-fixed and paraffin-r.mhedded 22 day old chondrocyte culture, which had been grown in the presence of ATP.
DETA~T,l~n DF.. ~C~PTION OF THE INVENTION
As hereinbefore mrntinnç-l, the present invention relates to a biological material cnmrrieing a cnntinllnllc layer of cartilaginous tissue recnnctit~lt~d in vitro which cu~ ins C~ cr - ~ with cartilage minerAli7Atinn In particular, it cont-Aini matrix vesicles, type X, type I and type II cnll~grnc, and it is Iq.nrir.h~d for chondlu~yh~;~ with alkaline phosphatase activity. The cells in the biological material synthesize large snlrhAtçd proteoglycans and they have a larger Ly~Ludyllamic size than proteoglycan syntheci7ed by non-mineralizing articular chon~u~,yte cultures.
The invention also relates to mineralized biological material having a hior.hto.mir.Al composition and physiological or~Ani7Atinn ~ SIA~ 11Y similar to the deep and cnntiFIlouc calcified cartilage zones of articular cartilage found in animals in vivo. The minPr~li7.çd biological material is ch~r~tctrri7~d by having mineral deposits both adjacent to the chondrocytes and within the territnri~l matrix away from the cells. The mineral deposits form in rel Atinnchip to matrix vesicles. Electron diffraction ~lP.m~ l ~ att;S that the mineral deposit crystals are co~ -oscd of calcium hydlu~y~ ti~. Alkaline phosphAtAce activity is ~l~trcted during mineralization.
The invention also relates to a method for producing a biological material of the invention cnmpTicing isolating chondrocytes from the deep zone of articular cartilage tissue, fonning a layer of the chondrocytes on a :~ul~sLIat~ cnltnTing the chondrocytes in growth media under suitable conditions so that the chondrocytes ~ccnmlll~t~ matrix and form cartilaginous tissue which is rnriched with components -AccociAtçd with cartilage minerAli7-Atinn The chondrocytes or cartilaginous tissue may be -ArlAitinnAlly cultured in the presence of a mineralizing agent, to form a c~ntinllnuc layer of mineralized cartilaginous tissue having a hiorh~ .micAl cc,lllposi~ion and physiological or~ni7-Atinn 5~hs~ lly similar to the deep and contiguous cAAlcified cartilage zones of articular cartilage found in animals in vivo.

The chondlu~;yLs used in the method of the invention may be isolated from articular cartilage from ~nim~lc, ~lcrelably hnm:mc, bovines, ovines, rabbits, most preferably hnm~nc The chondlu~,y~s may be isolated from adult or fetal tissue. In one embodiment of the invention, the chondlu~yLs are isolated from the metacarpal-carpal joints of calves.
Chondrocytes which are in the deep zone of articular cartilage are preferably isolated. Such chu~ u.,ylts may be obtained by icol~fing the lower 5-25%, pl~r~;lal)ly 15% of the articular cartilage tissue.
In a preferred embodiment of the invention, cells with an alkaline rhosrh~t~ce activity of at least about fourfold g~eater than that ~l~t~-cted in the same number of cells obtained 1 0 from the entire cartilage, are used to establish the cultures in the method of the invention. For example, cells with an alkaline rh~-sph~t~ce activity of at least 2 IlM PNP/hr/llg DNA, most ~l~,f~al~ly at least 14,uM PNP/hr/~g DNA, may be used to establich the cultures in the method of the invention.
The cl~ ,yt~,s may be isolated by seq~ nti~l enzyme ~1igectic~n t~hniq~ s such as those ~l~srrihed in Kandel et al, Biochem. Biophys. Acta. 1035: 130, 1990. For example, the cartilage may be treated with 0.5% pluleasc followed by 0.04% b~ct--ri~l coll~g~n~ce.
In accol.lallcc with the method of the invention a layer of chondrocytes is formed on a :,ulJsll~.~. Suitable substrates include bone, ~ngin~red biom~t~-ri~lc and porous tissue culture inserts, for example filter inserts. The substrate is optionally coated with an ~tt~rhm~.nt 2 0 factor. ~tt~rhm~ont factors are known in the art, see for ex~mrle7 Streuli and Bissell, J. Cell.
Biol. 110: 1405, 1990 and Buck and Horwitz, Arm, Rev. Cell Biol. 3: 179, 1987. Fx~mpl~.c of ~tt~rhmP.nt factors include type I collagen, type II collagen, type IV collagen, a synthetic peptide of a segm.ont of coll~g.on, ~l~relal)ly a fifteen amino acid sequence 766GTPGPQGIAGQRGW780 which is present in the ~ 1 chain of collagen (Rh ~tn ~g~r and Qian, 2 5 38th Annual Meeting of the Orthopedic Research Society 17: 106, 1992), fibronectin, gelatin, larninm, polylysine, viL~ul~eclin~ cytotactin, erhinon~-ctin, ~.nt~ctin t~-n~cr.jn thrombospondin, uvomorulin, biglycan, chondroitin sulfate, decorin"l~.rm~t~n sulfate, heparin, and hyaluronic acid. A ~l~;rell~d ~tt~r.hmPnt factor which may be used in the method of the invention is collagen, most ~ f~ldlJly type II collagen. When the substrate is coated it may be air dried and 3 0 sterili7~1 In a pl~r~ ;;d embodiment of the invention the substrate is a tissue culture insert known as Millicell CM~, (Millipore Corp., Bedford, MA, U.S.A.), pore size 0.4~m, coated with an .1l;..1,"~ factor,pl~f~,~al~ly type II collagen, 0.5 mg/ml 0.012N HCl (Sigma Chemical Co., St. Louis, MO, U.S.A.).

W O 97/17430 PCT/CA9~'~C7~9 Thechondlu.,yLsareseededonthe :~ul~:,llalc atacelldensityofaboutto lxlOsto 8 x 106 cells/cm2, preferably 2 x 106 cells/cm2. The chondrocytes seeded on the coated or mr.oslt~d s..~ are grown m suitable culture cnnrlitinnc FY~mplec of suitable culture media are known in the art, such as Ham's Fl2 and/or Dulbecco's mnrlifi~d Eagle's mr~ lm (DMEM).
Preferably DMEM is used after 4-5 days in culture. T_e culture merlinm may contain serum, for example fetal bovine serum in a conccillllalion range of about 2-20% and may further contain growth factors, and optinn~ y ascorbic acid. The culture media is applied above and below the substrate. The cells may be cultured at 37~C in a hnmitlified atmosphere supplclll~lLd with CO2. A cofactor for Iysyl oxidase to cross-linked cnll~glon for PYi~mple copper sulfate, may be used to retain more cnllAgton and provide thicker cartilage.
In a~l~,f~l~ .ho.l;...~ ofthe invention the isolated chondlu~,ylcs are grown in Ham's Fl2 media with 5% fetal bovine serum for 5 days, then t_e merlillm is /~hi~nged to DMEM
cn~lln;..;..g 20% fetal bovine serum, 25mM Hepes buffer and ascorbic acid (lO0 ,ug/ml, final concentration) .
The chondrocytes or cartilaginous tissue .-nric-.h~d for colllpul~ associated with car~lage minerAli7Ation i.e. biological material may be treated with one or more min~ rAli7ing agents which are capable of inducing miner~li7Atinn Suitable mineralizing agents include ~-~ly~ u~ , ATP, and rhncrhneth ~nnl ~mine The c~ . dt ion of the mineralizing agent used in the method of the invention is selected to provide a desired amount of minerAli7Atinn 2 0 By way of eYi~mple, the amount of ~-glyc~;ilu~ osrh~te which may be used in the method is about 2.5 to lO mM, final cQ~ ;nn The mineralizing agent is generally applied to the cultures after 2 days, ~lcrclal~ly 14 days, after initially seeding the chondrocytes. Generally the ... ;.. l;,;.. g agentis presentthroughoutthe culture period to get mi~Yimnm minerAli7z~tic n The cells are cultured for an ad~litinnz~l 6 weeks to obtain the mineralized biological material 2 5 described herein. The cells may be cultured for less than 6 weeks (or greater than 6 weeks) to obtain aproduct which may be suitable for some uses such as transplAntilti-~n or gene therapy.
The amount of ~ ;nn m the .n;..~ d biological material may be selected using particular culture con-liti-nc. For eY~mrle, smaller mineral deposits occur when the cultures are established with fewer mlmh~.r.c of cells from the deep 7one of cartilage, for 3 0 ex~mrle, adding increasing numbers of s--perfiriAl cells back to the deep cultures while still mAi.~li.;..i~g the same total cell number, de~l~ascs the size of mineral deposits. Mineral fnrm~tinn may also be ~-nh~nr.ed by inr lu~1ing ascorbic acid in the culture m~ lm In the cultures, the earliest c~lsific~tinn is seen around chondlu. yl~,s and some of these cells appear viable histologically even after six weeks in culture. Minimal amounts of minerAli7Atinn may occur around occ~cinnAl single cells during the first weeks of culture.

W O 97/17430 PCT/CA9~'~C7~9 g UlLI~L ucLu~ "";~i,1;nn d' ~ aLcs thatthe crystal deposits form in rel~tinn!chir to matrix vesicles. As mat~ix vesicles aTe present in the calcified cartilage, this suggests that these cultures may be mimir~ing the c~lcifir~tinn process as it occurs in vivo. The biorhl-mic~1 composition ofthe llfill~,lali~id tissue is s.~1.~li...l;~11y similarto the c~lcified zone of articular cartilage tissue.
The cells have detectable alkaline rhnsrh~t~ce activity at the initi~tinn of the cultures, and the amountofalkalinephns~.h,.l;~ceincreaseswithtimeduringminer7,1i7~tinn Chon~]lucyLt;;s from the mid and superficial zones of articular cartilage may becultured on top ofthe biological m~t--ri~1 of the invention to generate recnnctih1ted carlilage in vitro that resembles full thirl~n~s~c cartilage in vivo. In an embodiment of the invention, chondrocytes are isolated from the deep zone of articular cartilage and plated in culture as ~lr~crrihed above. The ~Lul~d-ul;yL~s ~I.c .. ~ c eYtr~r~11n1~r matrix to form carti1~gino.1q tissue.
Chondrocytes are then isolated from the mid and superficial zones of articular cartilage and are plated (e.g. at an optimal G~ r. .i . aLion of 3xl O6 cells/cm2) on the carti1 ~ginr~ c tissue formed by cells from the deep zone. Although cell cnl-rc~.l.dLions as low as 0.2x106 cells/cm2 can be used. The cultures are grown in suitable culture con~1ition!C in the presence of a mineralizing agent as described herein. By way of PY~mrle:, the cultures are grown in Hams Fl2 me~li11m c....li.;~.;..F~ 20% fetal bovine serum, and after about five days the m~-linm is r.h~nged to DMEM
with 20% fetal bovine serum ~"l,l~1 ..- ..l~d with lOrnM ~-gly~,clorhnsrh~t~, lOOIlg/ml ascorbic acid, and 25 mM Hepes buffer. The cultures are then m;.;~ cd for six weeks or longer. This 2 0 results in a lcc~ d llli-l~ oli~d cartilage tissue which has a deep mineralized layer and mid and sllrrrfiri~l non-mineralized layers ~ lly similar to articular cartilage tissue in vivo.
The biological m~teri~1 mineralized biological m~t~ri~1 and rec~n!ctitl1ted mineralized cartilage tissue of the present invention can be used as model systems for in vitro studies of cartilage st~ucture, function and development, and the calcific ~fi~ n process.
In accordance with one embodiment of the invention, the biological m~trri~1 mineralized biological m~tPri~1, and l~c~ d mineralized cartilage tissue may be used to test snhst~nces which affect c~lcificz~tic~n A system for testing for a sl1hst~nre that affects c~1cifir,~fion of articular cartilage tissue in accordance with the invention comrri~los c111tnring a biological m~trri~1, mineralized biological material or recnn~tit-~t~d mineralized cartilage tissue of the invention in the plcscllce of a s1~hst~nre which is ~ ec~d of ~ffrc*ng c~lrifir~tinn and d~ L~ - . . .; . .; .-g the hior.hr.mir,~1 composition and/or physiological organization of tissue generated in the culture, with the biorhrmir~1 cc,lll~û~iLion and/or physiological ul~ n of the biological m~t~ri~1 mineralized biological m~t~ri~1 or l~,co~ d mineralized cartilage tissue cultured in the absence of the s~bst~nre W O 97/17430 PCT/CA9Gi'~C7~9 The substance may be added to the culture or the chondrocyLes in the biological mAtP.ri~lc orl~c....~ rd minrrAli7~d carLilage tissue may be g~nPtirs~lly engineered to express the substance i.e. the chondrocytes may serve as an endogenous source of the s~lb~tAn~e Chondrocytes may be .onginPPred by viral or l~ uvh~ me~liAtPd gene transfer to produce a specific ~ e. The enginppred cells are constructed and mAintAined such that they release the snhstAnre into the medium for the desired period of time for the culture.
The system may be used to analyze the effects of s~lbstAnre(s) on dirr~l~,nL stages of r~lr~ifi~-Ati~n Effectsoncellsatveryearly, hllr.l.l.~.liAtP" andlate stages of cAlcificAtionmaybe evaluated by A~ceccing the biorhPmic~Al composition and/or physiological orgAni7Ation of the tissue and the minerAIi7Atic)n generated in the cultures at various times such as 2, 4, 6 and 8 weeks.
The biocllemirAl composition and/or physiological olga.~ m of the tissue generated in the cultures may be Ac~e~ced using the methods described herein.
In a ~ ;r~ ,d embodiment of the invention, the biological mAt~riAlc and l~C~ Ird minP.rali7Pd cartilage tissue of the present invention may be used in the testing of phArm~ceutical ~ U ons useful in the treatment of diseases of the joint, for P.YAmrlP7 osteoarthritis, inflAmmAtory ~lluop~Lllies, septic arthritis, and crystalline alLluup~lllies.
The biological mAtPriAlc and reconctihltPd mineralized carLilage tissue of the invention may also be implanted into the joints of patients to replace or repair ~lAmAged or 2 0 fl.. l~ .. ,l cartilage. The biological mAtP.riAlc and recnnctit~ltPd mineralized cartilage tissue can be used in the study and l~,dtlll~;lll of chc~l~udy~l,lasias. In adtlitinn the biological material can be used to test angiogenic factors as cartilage is normally resistant to vascular infiltration.
It is also c.~ lAtPd that the biological mAtPriAlc and l~,col.~ ..lPd mineralized cartilage tissue of the present invention can be used to enhance healing of bone L1~,LU1~S when 2 5 inserted into the site of a fracture.
The invention also co..lr...l~lAtPc using the biological mAt~riAlc and reconctitntPd mineralized cartilage tissue of the invention in gene therapy. Therefore, recombinant vectors c~ h~ g an ~Y--gP.nt-llc gene PnrQrling ahic~lngi~Ally active protein which is selected to modify the ~,lluly~c and phenotype of a cell to be infected may be introduced into chondrocytes in the biological mAt~riAlc and reconctihltpd mineralized cartilage tissue of the invention. An exogenous gene coding for a biologically active protein which corrects or cl~mppnc~tes for a genetic deficiency may be introduced into chondrocytes in the biological mAtPriAlc and reconctit~ltPd rnineralized cartilage tissue. For eYs~mrl~, TIMP (tissue inhibitor of metallul~lu~ases) could be ...llu~luced into the chon.llucyL~s so that the cells secrete this protein and inhibit the metallu~lul~,ases synth~-ci7Pd by chondrocytes locally in diseases such as W O 97/17430 PCT/CA~G~C/~9 O~I~Oa~ iLiS and Illk....~ .loitl arthritis. A gene could also be inserted to metabolize iron which would be useful in the LltaLulGll~ ofth~l~qc~cmia The expression of the exogenous gene may be .d by l .~ ~ C.~.; --~ the expression levels of a select~hle marker encoded by a selection gene cnnt~in~d in the recomhinAnt vector.
The following non-limiting examples are illu~llalivG of the present invention:
F.Y~m~l21cs The following m~t~i~lq and methods were utilized in the investigations outlined in the e~zlmrles:
Cl~u~d~ v~ te Culture: The articular cartilage from the metacarpal-carpal joints of calves was exposed and the majority of the caTtilage was removed and discarded. The r~m:lining deep articular and calcified caTtilage was ~liqqectrd offthe sl~brhnnrlral bone and collecte.l The chomllv~;y~es were isolated from this tissue using sc~lenti~l enzyme ~ligestion and plated at 5x10~ cells/cm2 on filter inserts (MilliporeRCM) coated with type II collagen as described in U.S. Patent Serial No. 5,326,357 and Boyle, J. et al; Osteoarthritis and Cartilage 3: 117-125;
1 5 1995 which are ulcul L~u.. ~d herein in their entirety by l~rG~ ce. The cells were plated in Hams F12 cn--l;~ g 5% fetal bovine serum, and 25mM Hepes. After 5 days the m~ lm was changed to Dulbecco's Modified Eagle's Medium (DMEM) c~ .i . .; . .g 20% fetal bovine serum, 25 mM Hepes and ascorbic acid (lû0 ,ug/ml, final concentration). The meflillm was changed every two to three days and f~esh ascorbic acid was added each time. After two weeks in culture ~-glycerorlhosr-h~te (10 mM, final conrf.ntration) was added to the m~rlillm In selected .o~rPrim~.ntq, the concentration of ~-gly-;~.ul-hosrh~te was varied from 0 to 10 mM.
Control cultures were established using cells isolated from the entire cartilage as ~lec- . ;l~ed in U.S. Patent Serial No. 5,326,357 which is incorporated herein by reference. These cells were m~int~in~l in Hams F12 with 20% fetal bovine serum, 25mM Hepes, and ascorbic 2 5 acid but they did not receive ~-gly.,.,.. ,phnqph~tr Histological .Ar- ' of Chondrocyte Cultures: The cultures were harvested at vaTying times up to 8 weeks after plating, fixed in 10% buffered formalin and paraffin rmher1~
Sections (5 ~n) were cut and stained with h/~m~to~ylin or eosin to assess the celhll~nty, toluidine blue to ~lrmonetrate the ~ ,sencG of s~llph~t~d proteoglycans, or von Kossa to 3 0 ~lem- nqtrate the miner:~li7~tion Alkaline Phosph~t~ce Activity: At varying times, the cultures were removed from the filter mto Buffer A (0.1% Triton X, 0.2M Tris HCI pH 7.4, 45.7 mM NaCl) and snnirattq.d for 15 sec.
on ice. The solution was clarified by cl-.ntrifilg~ti~m for 20 min at 4~C at 700 xg and stored at -20~C umtil used. Alkaline phosph~t~qe activity was det~nnin~o-d by mixing aliquots of the 3 5 extracts with 0.06M solution of p-nitrophenol phosph~t~ (Sigma (~h.omir:ll St. Louis, MO) in W O 97/17430 PCT/CA9~ 7~9 0.07M sodium ballJ;Lulle pH 9.3 (BDH Inc., Toronto, Canada) for 1 hr at 37-C. The reaction was stopped by addition of 50111 of 1.5N NaOH. The assay was done in 96 well plates and analyzed ~euL,~hu~ cL,ically at a wavelength of 405 nm (Titertek Mlllti~l ~n) (Kato, Y., et al., Proc.
Natl. Acad. Sci. 85:9552-9556, 1988). p-Nillupllellol was used to generate the standard curve.
Results were nnrms~li7rd against DNA content. All eXperim~ntc were done in triplicate and repeated at least three times.
DNA Content of Cultures: The cultures were harvested at varying times, and digested with papain and the DNA content ..,~ I.id using Hoescht 33258 dye (Polysc.ienres Inc. W~rringtrJn PA) and nuulu~ LIy as ~1rcrrihed previously (Boyle et. al., Osteoarthritis and Cartilage, 3: 117-1 0 125, 1995).
~ - ' u.. Mi~, os~u~,y; The cultures were harvested at four weeks, fixed in 2% glutaraldehyde in 0. lM sodium cacodylate buffer, post-fixed in 1% osmium tetroxide, de-hyL~Led in graded ethanol series, followed by propylene oxide and ~mbed(led in Spurr epoxy resin. Thin sections were cut, stained with lead citrate and uranyl acetate and e~r~mined ulLI~Llu~;~ul~lly using a 1 5 Philips 430 L~ electron rniwuscu~e. To ~1~l r ~ . . .; . .~ mineral composition, the crystals were ex~min~d by selected area electron diffraction and the pattern gener~ted cu~ al~d to known standards.
Analysis of Collagens in the Matri~: To r.X:~mine collagen synthesis in these cultures, the chondrocytes were inr~lhatrd with [14C] proline (4,uCi) for 24 hours. The collagens were extracted with pepsin (100 ~g/ml in 0.5M acetic acid) [Wor~hin~tr,n BiorhPmic~l Corp., Freehold, NJl for 48 hrs at 4DC. The fli~esti~m was stopped by addition of 4x T ~mmli buffer.
The extract was s~a~,d on an 8% SDS-polyacrylamide gel and transferred to nitrocellulose for Western blot analysis and autoradiography. Blots were incubated with antibodies reactive with either type I collagen (Sout_ern Biotechnology Assoc., AL, USA), type II collagen 2 5 (Southem Ric)terhnnlogy Assoc., AL., USA), or type X collagen (Gibson, G. Trans. Orthop. Res.
20:28, 1995) overnight. R~iliviLy was det.-ct~d using affinity purified goat anti-rabbit IgG
antibody conjugated to alkaline phocrh~t~e. Nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphnsrh~te (NBT/BCIP) were added for substrate and colour reaction (GIBCO BRL, Bnrlingtnn, Ont, Canada). The blot was then exposed to X-oMat AR film for 1 week.
3 0 Analysis of Newly Sy.. ~l.r ~:-cd Proleo~ly~ans: To analyze proteoglycan biosynthesis in the mineralized cultures, the cultures were inrllb~tPd with [35S] sulphate (l ,uCi/ well) for 24 hrs prior to ll~u v~ ing. The proteoglycans were extracted with 4M gll~ni~line HCl in 50mM sodium acetate, pH 5.8 c~...l7.;..;.-~ 0.1 M 6-~minohP~r~noic acid, 50 mM b~n7~mi~1in~ HCl, 10 mM
EDTA and 5 mM N elllyl~ imi~ for 24 hrs at 40C. The nnfligest~d mineral was removed by 3 5 cf .ntrifi~ ti~n for 5 min at 4uC. The proteoglycan monl~mer size was ~ minrd by Sepharose -CL~2B column chromatography (lx100 cm) under dissociative contlitinn~ at 4~C. A flow rate of 6m1/hr was used. The elution profile was analyzed for its partition coefficient, Kav [Kav=(Ve-Vo)/(Vt-Vo)], where Vt= total volume, Vo= void volume, and Ve= elution volume.
Vt was det~rmin~d using [35S] S04 and the void volume determin~d using dextran slllrhz.tl-.

CHARACTERIZATION OF THE MINERALIZED CHONDROCYTE CULTURES
Determination of the Enrichment of Chondrocytes from the Deep Zone: As alkaline rhosl~h .~ activity is detected in cells at or above the c~lcifi~d zone of aTticular cartilage, this enzy~ne was used as a marker to assess the ~ .nril-hm.-nt of these cultures with cells from the deep cartilage. Cells with an alkaline phosphatase activity of at least 2 ~M PNP/hr/106 cells, which r~l~s~llled at least a fourfold increase in alkaline phosphatase activity when cO~ d to the alkaline rhosrh~t~ce activity detect~d in the same number of cells obf~inPd from the entire cartilage (datanot shown), were used to establish the cultures. Cells with alkaline rhn~ph~tA~e activity less than this did not mineralize as well or as rapidly. On average the alkaline phnsrh~f~e activity of the cells isolated from the deep layer of cartilage was 4.11 0.8 ~M
PNP/hr/ llg DNA (mean-l SE). In contrastthe alkaline I~hn~l~hA~ e activity of cells isolated from the upper two-thirds of the cartilage which had been ~1i c~ected off and were not used to establish the cultures was 0.3+0.05~M PNP/hr/ ~g DNA (mean ~SE) which confinn~ the ~nrichmerlt of the cultures with alkaline rhnsph~t~e co~ ,.illg chondrocytes.
2 0 Histological Appearance of the Chondrocyte Cultures: Figure 1 shows the histological ,e~ulce of form~lin and paraffin embedded chondrocyte cultures harvested at two (~igure lA), and 8 (Figure lB) weeks. The filter (F) on which the cells are grown is present and at two weeks the cartilaginous tissue does not show c~lcificafinn (Von Kossa, m~gnific~tinn x 400).
The chonLu-,yL~s during the first two weeks in culture aC cnnmll~tf d extr~r~olhll~r 2 5 matrix to form a continuous layer of cartilaginous tissue which cnnt~in~d snlrh~t~d proteoglycans as ~L.. ~ t~,d histologically by tol--i~lin~ blue staining (Figure lA). The cells in the lower half of the tissue appeared hypertrophic and were surrounded by large lacumae histologically. Once the tissue had formed, minerp~li7~tinn was induced by the acl.litinn of ~--glycerophosphate. The calcification occurred rapidly as the deposits could be vi~ .1i7ed by phase contrast micluscu~y within one day of adding ~-gly~ uplln~rh~tp in many of the cultures. Histological sections of the cultures d~mc-n~trated that the mineralization occurred around single cells mthe lower half of the cartilaginous tissue and the extent of miner~1i7s.tinn increased over time forming a cnntimlc-us layer of mineralization (Figure lB). Progressive ;lnl;, II;nn was not obs~l v~id hictologi~lly when the cultures were m~int:3in~d in Hams F12 instead of DMEM and when the col~ ,l,aLion of ~-~ly~ ulJhosphate was less than 2.5 mM

CA 02236807 l998-05-04 (data not shown). ~-gly~ Jphosph~te, at c. "c~ .aLions between 2.5 and lOmM was able to induce minerS~ tinn but at a slower rate. Cultures est~blich~d using chondrocytes obtained from full thirkn~ cc of caltilage or from just the upper two-t_irds of the articular cartilage did not form a contimlous layer of mineralized tissue.
Determ~nation of Alkaline~,l, _, 7 ~n~eActivity of the Cultures: As alkaline phnsph~t~ce has been imp~ tpd in apatite crystal fnrm~tion (Whyte, M.P. Alkaline phnsrh~t~ce: physiological role explored in hypophnsph~t~ci~ In: Peck WA (ed.). Bone and Mineral Research, 6th Ed.
Elsevier Science Pllhlich~rc, A~ dalll, 1989:175-218 and Yoon, K.; Golub, E.E.; Rodan, G.A.
Alkaline phncph~lts~ce cDNA tr~ncfPct~cl cells promote calcium and rhosrh~te deposition. In:
(~TlimrhP.r MJ, Lian JB (eds.) Pl~)cee~ gc of the Third Tnt~rn~tinn~l Conference on the (~hPmictry and Biology of Mineralized Tissues. Gordon and Breach Science Publishers, New York, 1989;643-652) and because under some culture cnn-litinnc, chon~Lu~iy~s can lose this enzyme activity (Xu, Y. et al., J. Rheum. 21(5):912-919; 1994), the cells in culture were assayed for the presence of alkaline pho5rh~t~ce activity.
Figure 2 is a graph showing alkaline rhn5rhs~t~ce activity of cultures established from cells from the deep cartilage after two weeks in culture which was just prior to ;nn (day o) and during matrix mineralization. The results are G~ scd as the meanSE of one lt~ ;llklLiV~ .lt;lilllCIll, which was repeated three times. Each time point was done in triplicate.
2 0 As ~ al~cl in Figure 2~ the cultures cnntinllpd to express alkaline rhosl?h~t~ce activity during the culture period. The enzyme activity increased over time. The ci~nifi~nre of the increasing alkaline phosphatase activity is unknown but has been shown to occur in other ulg cultures (Iwamoto, M.et al;Dev. Biol. 136:500-~07; 1989, Wu, L.N.Y. et al; J. Biol.
Chem. 264(35):21346-21355, 1989).
2 5 Wrastructural Chu, ,.. ~., .4ation of the Mineral: The mineralized cultures were P.~:lminPd by electron micn~sc~y to ~let~-rminp~ whether matrix vesicles, which have been implicated as the site of initial crystal fnrm~tion (Wuthier, RE. ~r.h~nicm of matrix vesicle mp~ ted ...;u...~l;,,.~;nn of cartilage. ISIAtlas Sci. Biochem. 1:231-241; 1988) arepresentinthematrix ofthese cultures. Ullla~llu~ lly, cho~ ).;y~s were sunounded by matrix cnnt~ining collagen 3 0 and proteoglycans (Figure 3A). Matrix vesicles were present in the matrix and crystals were seen adjacent to matrix vesicles (Figure 3B). The crystals had an ulLla~Llul;~ul~l morphology similar to that of lly.llui~ya~atite crystals. Crystal deposits were seen both adjacent to the chondrocytes and within the t~-rritnri~l matrix away form the cell. Although it is possible that these latter deposits were actually close to cells which were not in the plane of section. The W O 97/17430 PCT/CA9~ 7~9 c}ystals were analyzed by selected area electron diffraction which cl.~monefrated that they were composed of hydlu~ya~a~ (Figure 3C).
Composition of the Extrnre77~ r Mafrix: As the extr~relhll~r matrix of cart;lage contains char~rtrrietic macromolecules such as large proteoglycans (aggrecan) and specific types of cnllsigt-.ne (Lovell, T.P. and Eyre, D.R Trans. Orthop. Res. Soc. 13:511; 1988; Oegema,T.RJr.;
Th. ,. . ~l~s~ .. . RC. Jr. The wne of calcified cartilage. Its role in osteoarthritis. In: KllPttner, K. eds.
Articular Cartilage and O~l~OallllliLis New York: Raven Press; 1992:319-331; and Oegema, T.R. Jr.; Thnmpsnn RC. Cart;lage-Bone T.~ e (Tidemark). In: Brandt, K. ed. Carlilage Changes in O~oa~ is. Indiana School of Medicine p~hlir-~tinn Basel: Ciba-Geigy; 1990:43-1 0 52) the matrix cu~ o~i~ion of the cultures was eY:~min~o~ To assess the types of coll agen in the matrix, the matrix was digested with pepsin. The pepsin extracts were subjected to SDS PAGE
and either autoradiography or Westem blot analysis.
Figure 4A shows an autoradiogram of pepsin extracted [14C] proline labelled collS~g~ne ~y~ ~lh~ d by chondrocytes after formation of the cartilaginous tissue (14 days) and 1 5 when the tissue was mineralized (28 days). Figures 4A, shows bands indicative of type II, type X and type I crll~g~lc in the matrix ofthe mineralizing chondrocyte culture. Bands suggestive of type XI collagen, which has been detected in the çs~lcified cartilage (Lovell, T.P. and Eyre, D.R. Trans. Orthop. Res. Soc. 13 :511; 1988), were also seen on the autoradiogram.
The ~ ce of the cnll~genc was c~ cl by Western blot analysis. In particular, 2 0 Figure 4B shows a Western blot analysis of collagens extracted from mineralized cultures (day 28) (E) using antibodies reactive with type II collagen (II), type I collagen (I), or type X collagen (X). The a~ lU~fidte purified collagen type was used as a standard (S) for each blot. The types of collagens syntheci7~d by the chondrocytes did not change during matrix mineralization.
To e~mine the proteoglycans in the matrix, the [35S] S04 labelled proteoglycans were gn~niflinillm ~ aL~d from six week old mineralized cultures. Figure 4C shows the proteoglycan elution profile of newly syntheei7~d proteoglycans extracted from 42 day old mineralized cultures. [35S] S04 labelled proteoglycan mnnnml-r size was ~l~lr....i.lf d by Sepharose 2B column chromatography under ~1iesori~*ve cnn(litinne Figure 4C is adLiVt; profile from an ~ h~ I that was repeated five times. Analysis by column 3 0 ~ ullla~graphy under (1ieeor,i;~tive cnn~itinnc demonstrated that the proteoglycans had a large hydrodynamic size (Kav= 0.26~t0.03) and were polydisperse (Figure 4C). These proteoglycans were larger than those synth~ei~cl by chondrocytes in non-mineralizing cartilaginous tissue formed in vitro.
The studies illustrated herein describe an articular chondrocyte culture system in which cartilaginous tissue is formed in vitro which can be induced to mineralize. The WO 97/17430 PCT/CA95.'vC7~9 chondrocytes used to ect~hlich these cultures differ from previously described non-mineralizing articular chulldlu~,yle cul~res in that the cllulldlu~,yh s were obtained from the deep zone (lower 15%) of articular cartilage and not from the entire cartilage. This region was selected for cell iCc I ~inn fortwo reasons. Firstly, it contains cells with alkaline rhosrh~t~ce activity, an enzyme which is involved in min~r~li 7~tion (Yoon, K.; Golub, E~E.; Rodan, G.A. ALIcaline rhnsrh~t~ce cDNA transfected cells promote calcium and rhnsrh~t~ deposition. In: ~Tlim~her MJ, Lian JB
(eds.) Procee~lingc of the Third TntP.rnAfional Conference on the (~hemictry and Biology of Mineralized Tissues. Gordon and Breach Science P~bliCh~rc, New York, 1989;643-652) and secondly, this region of cartilage can undergo miners~li7~tion in vivo in~licslting that the cells have the potential to synthesize matrix components that favor miner~li7~tinn umder the a~J~lulJliatc cnn-litionc The results suggest that the mineralizing chondrocyte cultures contain, as has been eY~min~d to date, some of the same components as the c~kified cartilage (Gannon, J.M.et al, J. Orthop. Res. 9:485-494; 1991; Oegema, T.R Jr.; Thompson, RC. Jr. The zone of c~lcified cartilage. Its role in osteoalLluiLis In: Knettner, K. eds. Articular Cartilage and Osteoarthritis.
New York: Raven Press; 1992:319-331; Oegema,T.R Jr.; Thompcon RC. Cartilage-BoneT~ ri~e (Ticlem~rk). In: Brandt, K.ed. Cartilage Changes in Osteo~ulluiLis. Indiana School of Medicinepllhlic~tinn Basel: Ciba-Geigy; 1990:43-52; andWardaleJ.R andDuance,V.C.,J.
Cell. Sci. 105:975-984; 1993.), in particular those thought to be involved in cartilage miner~li7~tion, such as matrix vesicles, type X coll~gen and alkaline phnsrh~t~ce activity (Poole, RA. et al., Anat. Rec. 224:167-179; 1989). The crystals that formed in these mineralizing cultures were hydlu~ya~Lile~ the crystal ty-pe present in calcified cartilage.
Furthermore, similar to calcified caTtilage in vivo, ulLl~L~u~;Lulal çY~min~tinn d~ ,llon:,Ll ~LLt;d that the cry-stal deposits formed in rel~tinnchir to matrix vesicles. Although the components that have been shown to be involved in miner~li7~tinn were present in these cultures, ~-~lyc~ hosphate was required for the progressive miner~li7~tion of the matrix. It has been suggested that the c~lcific~tinn which occurs in the presence of ~-~;ly~ ol)llosrh~te7 which is acting as arhocrh~te donor, may be cu~r~iludl (~lu~,hl~,~, P. et al; J. Cell. Biol. 109:2537-2545;
1989), but this is unlikely to be the citn~tinn in these cultures. It was found that the amount of 3 o ~ ",li~ .l;nn could be infl~ nced by the number of cells from the deep zone in the culture. If the cultures were established at the same plating density but the deep cells were diluted with increasing mlmberc of chondrocytes isolated from the superficial zone, this resulted in a decrease in the size of mineral deposits as clel~ ....;..~d by light microscopic ex~min~tinn of histological sections of the cultures (data not shown). Furthermore although ~-35 i ~ly~;~.ul.h-sph~te was required, a low cnnr~ntration of ~-gly~ o~ osph~tt. (2.5mM) was W O 97/17430 PCT/~A~6~'~C7~9 snfficient to induce miner~li7Atic n The chondrocytes in these cultures ms~int~in~d their phenotype as they synthesi7ed type II collagen and large s..lphAted proteoglycans, which are characteristic of dirrG~ iated chondrocytes. However, type I collagen was also present. T_is collagen type is not usually detected in normal hyaline (non-mineralized) car~lage and under some culture con-litic ne its synthesis is considered suggestive of chondrocyte dcli~ ti-m ImmunonuulGsc.,,lcGstudies have shown that type I collagen is present in the cAlcifie~l zone of articular cartilage (Wardale, J.R and Duance, V.C.; J. Cell. Sci. 105:975-984, 1993 ) so its synthesis by cllullLu~,ylGs in these cultures likely reflect the cell phenotype. The proteoglycans synthe~i7ed bythe chul~u~yLGs in .. ;.. .~,li,;,~g culture had a larger hydrodynamic size than proteoglycans synthesi7ecl by non-mineralizing articular chondrocytes (cells obtained from full thir1 n~
cartilage) grown on filter inserts (Boyle, J.et al; Osteoarthritis and Cartilage 3: 117-125; 1995).
Studies ~x;..,,;,,;,~g the size of proteoglycans extracted from the di~.lGlll layers of articular cartilage from superficial to deep have d~. nnn~ated that the hydrodynamic size of the 1 5 proteoglycans under tli~oçi~tive c~ n~lition~ were similar but not id~ntic~l in size in all zones (Korver, G.H.V. et al;Matrix 10:394-401; 1990; Mitrovic, D.R and Darmon, N. Osteoartl~ritis and Cartilage 2: 119-131,1994). The hydrodynamic size of the proteoglycans synth.?ci7Pcl by chull~u.;yLGs in the deep zone of human articular cartilage had a (Kd) ranging from 0.18 to 0.22 (Mitrovic, D.Rand Darmon, Osteoarthritis and Cartilage 2: 119-131; 1994). The cells of other 2 0 types of mineralizing cartilage, such as epiphyseal plate chondrocytes and embryonic limb bud cells, have also been shown to synthesize large proteoglycans (Hascall, V.C.et al; J. Biol. Chem.
251:3511-3519; 1976; Plaas,A.H.K. and Sandy,J.D. Mat~ix 13:135-147; 1993; and Silbermann, M. et al; Bone 8: 117-126; 1987). For epiphyseal chondrocytes, the hydrodynamic size of the proteoglycans synthe~i7~d varied ~leplq.n.ling on the location of the cell in the growth plate (Plaas, A.H.K. and Sandy, J.D. Mat}ix 13:135-147, 1993). F,~ lyullic mesenchymal cells that diLLGIGllLiate into chonlllu~,y~, :jylll~ G pluLGo~;ly~ s other than aggrecan (Plaas, A.H.K. and Sandy, J.D.; Matrix 13:135-147; 1993; and Shaklee, P.N. and Conrad, H.E. J. Biol. Chem.
260:16064-16067; 1985). Versican (PG-M) is one the proteoglycans which has been i~1entifi~d and its characterization d~.nno~ aLGd that it has a larger core protein than aggrecan (Plaas, - 30 A.H.K. and Sandy, J.D. Matrix 13:135-147; 1993). Versican has also been rl~-t~ cted in osteoarthritic articular cartilage (Nishida,Y et al.; Osteo~LllliLis and Cartilage 2:43-49, 1994).
In c~n~hl~ion, the mineralizing articular chon~Lu.yLGs cultures ~Ai~ their ~1~CnULY~C in v~vo and should be useful as a model to ~ nine the metabolism of cells from the deep zone of articular cartilage and the mineralization of cartilaginous tissue.

E~MPLE 2 Chondrocytes from the mid and ~ l zones of articular cartilage were cultured on top of the mineralized carlilaginous tissue described above. Chondrocyte cultures are grown in Hams Fl2 m~rlinm c.~ i/tg 20% fetal bovine serum as rlesrribed above, and after about five days the me~1illm is changed to DMEM with 20% fetal bovine serum supplemented with lOmM ~-~,ly.;elu~hctcrh~te7 lOO~lg/ml ascorbic acid, and 25 mM Hepes buffer. The cultures are then ms~intztined for six weeks or longer. This results in a recnn.ctit~ltçd mineralized eartilage tissue which has a deep min.orstli7ed layer and mid and superfieial non-mineralized layers sllhct~ntisllly similar to artieular cartilage tissue in vivo. In particular, Figure S is a ph~ttrtmir.rograph of 49 day old culture showing superficial and mitl7rtne chondrocytes cultured on cartilaginous tissue formed by the deep cells. Cartilaginous tissue is present and mineral deposits are present in the tissue generated by the deep cells only (Von Kossa stain).
Figure 6 is a phrttrtmirrograph showing the histological a~ e~r~ce of formalin-fixed and paraffin-~mhçrlrled cLull~llu-iy~ eulture. The cultures have been inrllbstted for 8 days in the ~L~,.,~lce of ATP, and .. h,~ A1;ctn (1~) is seen in the lower zone of the tissue. The filter insert is still present beneath the cartilaginous tissue (F).
Having illu.,llaled and described the principles of the invention in a pl~r~ c;dembodiment, it should be appreciated to those skilled in the art that the invention can be modified in arrangement and detail without de~tule from such principles. We elaim all 2 0 morlifir~ti tnc eoming within the scope of the following elaims.
All publir zl*rtnc~ patents and patent strpli~sttir~nc are herein incol~Julal~d by referenee in their entirety to the same extent as if each individual publication, patent or patent applieation was speeifieally and individually inrlir~ted to be incul~olaL~d by reference in its entirety.

Claims (13)

I CLAIM:
1. An isolated and purified mineralized biological material consisting of acontinous layer of mineralization characterized by chondrocytes having alkaline phosphatase activity and surrounded by matrix containing type I, type II and type X
collagens, sulphated proteoglycans having a large hydrodynamic size, matrix vesicles and calcium hydroxyapatite crystal.
2. An isolated and purified mineralized biological material consisting essentially of a continuous layer of mineralization characterized by chondrocytes having alkaline phosphatase activity and surrounded by matrix containing type I, type II and type X
collagens, sulphated proteoglycans having a large hydrodynamic size, matrix vesicles, and calcium hydroxyapatite deposits.
3. An isolated and purified mineralized biological material as claimed in claim 1, wherein the chondrocytes are transformed with recombinant vectors containing an exogenous gone encoding a biologically active protein which corrects or compensates for a genetic deficiency.
4. A method for producing an isolated and purified mineralized biological material as claimed in claim 1 comprising (a) isolating chonitrocytes from the lower 15% of animal articular cartilage tissue having an alkaline phosphatase activity of at least 2 µM
PNP/hr/µg DNA; (b) forming a layer of the chondrocytes an a substrate wherein the substrate is bone, an engineered biomaterial or a porous tissue culture insert; (c) culturing the chondroxytes in growth media under suitable conditions so that thechondroxytes accumulate matrix and form cartilaginous tissue which contains components associated with cartilage mineralization, and (d) culturing the cartilaginous tissue in the presence of a mineralizing agent selected from the group consisting of glycerophosphate, ATP, phosphocthanolamine, to form a continuous layer of mineralized cartilaginous tissue comprising of a continous layer of mineralization characterized by chondroxytes having alkaline phosphatase activity and surrounded by matrix containing type I, type II and type X collagens, sulphated proteoglycans having a large hydrodynamic size, matrix vesicles and calcium hydroxyapatite crystal deposits,
5. A method as claimed in claim 4 wherein the chondrocytes are isolated by sequential enzyme digestion techniques.
6. A method as claimed in claim 4 wherein the chondroxytes are seeded on the substrate at a cell density of about 1 x 10 5 to 8 x 10 6 cells/em2.
7. A method as claimed in claim 4 which further comprises transforming chondrocytes in the mineralized biological material with recombinant vectors containing as exogenous gene encoding a biologically active protein which corrects or compensates for a genetic deficiency.
8. A method for producing an isolated and purified mineralized biological material as claimed in claim 7 which further comprises after step (c) culturing chondrocytes isolated from the mid and superficial zones of animal articular cartilage tissue on the cartilaginous tissue in the presence of a mineralizing agent to from a material comprising a minerialized biological material comprising a continous layer of mineralization characterized by chondrocytes surrounded by matrix containing type I, type II and type X collagens, sulphated proteoglycans having a large hydrodynamic size, matrix vesicles and calcium hydroxyapatite crystal deposits, and a mid andsuperficial non-minerialized layer adjacent to and continous with the mineralized biological material corresponding to the mid and superficial layers of articular cartilage in vivo.
9. A method for testing for a substance that affects calcification of articular cartilage tissue comprising coculturing an isolated and purified mineralized biological material as claimed in claim 1 in the presence of a substance which as suspected of affecting calcification, and determining the biochemical composition and/or physiological organization of the mineralized biological material generated in the coculture, with the biochemical composition and/or physiological organization of the mineralized biological material cultuted in the absence of the substance.
10. A method as claimed in claim 9, wherein the substance is added to the coculture, or chondrocytes in the isolated and purified mineralized biological material are genetically engineered to express the substance.
11. A method as claimed in claim 9 wherein the substance is a pharmaceuticalpreparation which is suspected of being useful in the treatment of diseases of the joint.
12. A method of replacing or repairing damaged or deficient cartilage in a joint of a patient comprising implanting an isolated and purified mineralized biological material as claimed in claim 1 or 2 in the joint of the patient.
13. A method of enhancing heating of a bone fracture in a patient comprisinginserting an isolated and purified mineralized biological material as claimed in claim 1 or 2 into the site of a fracture.
CA002236807A 1995-11-06 1996-11-05 Reconstituted mineralized cartilage tissue Abandoned CA2236807A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US727995P 1995-11-06 1995-11-06
US60/007,279 1995-11-06
US70662596A 1996-09-06 1996-09-06
US08/706,625 1996-09-06
PCT/CA1996/000729 WO1997017430A1 (en) 1995-11-06 1996-11-05 Reconstituted mineralized cartilage tissue

Publications (1)

Publication Number Publication Date
CA2236807A1 true CA2236807A1 (en) 1997-05-15

Family

ID=26676769

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002236807A Abandoned CA2236807A1 (en) 1995-11-06 1996-11-05 Reconstituted mineralized cartilage tissue

Country Status (8)

Country Link
US (1) US6464729B1 (en)
EP (1) EP0862616B1 (en)
JP (3) JP2002515731A (en)
AT (1) ATE402994T1 (en)
AU (1) AU7274696A (en)
CA (1) CA2236807A1 (en)
DE (1) DE69637619D1 (en)
WO (1) WO1997017430A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AU7274696A (en) 1995-11-06 1997-05-29 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
US20020111695A1 (en) * 1995-11-06 2002-08-15 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
US6369295B1 (en) * 1998-10-08 2002-04-09 University Of Hong Kong Uses of transgenic mouse containing a type X collagen mutant
US6767928B1 (en) 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
US6541022B1 (en) 1999-03-19 2003-04-01 The Regents Of The University Of Michigan Mineral and cellular patterning on biomaterial surfaces
US6179840B1 (en) 1999-07-23 2001-01-30 Ethicon, Inc. Graft fixation device and method
US20020095157A1 (en) 1999-07-23 2002-07-18 Bowman Steven M. Graft fixation device combination
JP2003512110A (en) * 1999-10-15 2003-04-02 マウント・シナイ・ホスピタル Synthetic substrate for tissue formation
WO2002000142A2 (en) * 2000-06-29 2002-01-03 Mount Sinai Hospital Intervertebral disc
US6638312B2 (en) * 2000-08-04 2003-10-28 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa (SIS)
US8366787B2 (en) * 2000-08-04 2013-02-05 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
CA2365376C (en) 2000-12-21 2006-03-28 Ethicon, Inc. Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US7819918B2 (en) * 2001-07-16 2010-10-26 Depuy Products, Inc. Implantable tissue repair device
WO2003007839A2 (en) 2001-07-16 2003-01-30 Depuy Products, Inc. Devices form naturally occurring biologically derived
US8025896B2 (en) 2001-07-16 2011-09-27 Depuy Products, Inc. Porous extracellular matrix scaffold and method
AU2002316696B2 (en) * 2001-07-16 2007-08-30 Depuy Products, Inc. Cartilage repair and regeneration scaffold and method
WO2003007790A2 (en) 2001-07-16 2003-01-30 Depuy Products, Inc. Hybrid biologic/synthetic porous extracellular matrix scaffolds
EP1416888A4 (en) 2001-07-16 2007-04-25 Depuy Products Inc Meniscus regeneration device and method
US7476257B2 (en) * 2001-09-15 2009-01-13 Rush University Medical Center Methods to engineer stratified cartilage tissue
US20040078090A1 (en) 2002-10-18 2004-04-22 Francois Binette Biocompatible scaffolds with tissue fragments
US7824701B2 (en) 2002-10-18 2010-11-02 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
US8197837B2 (en) 2003-03-07 2012-06-12 Depuy Mitek, Inc. Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof
US8226715B2 (en) 2003-06-30 2012-07-24 Depuy Mitek, Inc. Scaffold for connective tissue repair
US10583220B2 (en) * 2003-08-11 2020-03-10 DePuy Synthes Products, Inc. Method and apparatus for resurfacing an articular surface
EP1681067A1 (en) * 2003-10-15 2006-07-19 Japan Science and Technology Agency Implant for regenerating bone or cartilage with the use of transcriptional factor
US7316822B2 (en) 2003-11-26 2008-01-08 Ethicon, Inc. Conformable tissue repair implant capable of injection delivery
US7901461B2 (en) * 2003-12-05 2011-03-08 Ethicon, Inc. Viable tissue repair implants and methods of use
US11395865B2 (en) 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US8221780B2 (en) 2004-04-20 2012-07-17 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8137686B2 (en) 2004-04-20 2012-03-20 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
AU2006307647B2 (en) * 2005-10-24 2012-09-13 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method and device for synovial cell-charged collagen membrane or gel
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
RU2519119C1 (en) * 2013-02-26 2014-06-10 Федеральное государственное бюджетное учреждение "Всероссийский центр глазной и пластической хирургии" Министерства здравоохранения Российской Федерации Method of treating degenerative and inflammatory-degenerative arthropathies
US10195044B2 (en) * 2013-07-12 2019-02-05 Sinai Health System Intervertebral disc implant
US10016528B2 (en) * 2013-09-09 2018-07-10 Eran Rosines Biologic prosthesis and methods of production and use
RU2717345C1 (en) * 2019-11-19 2020-03-23 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for treating osteoarthritis of knee joint

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703575A (en) 1970-12-23 1972-11-21 Heinrich Thiele Reconstructed cartilaginous tissue and method of implanting it into the human or animal body
US4356261A (en) 1980-04-22 1982-10-26 Rush-Presbyterian-St. Luke's Medical Center Anti-invasion factor containing cultures
IL68218A (en) 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4757017A (en) 1984-09-14 1988-07-12 Mcw Research Foundation, Inc. In vitro cell culture system
US5160490A (en) 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
US5902741A (en) * 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US5037656A (en) 1986-12-04 1991-08-06 Millipore Corporation Porous membrane having hydrophilic and cell growth promotions surface and process
US4846835A (en) * 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5053050A (en) 1988-04-29 1991-10-01 Samuel Itay Compositions for repair of cartilage and bone
US4904259A (en) 1988-04-29 1990-02-27 Samuel Itay Compositions and methods for repair of cartilage and bone
US5067962A (en) 1989-04-18 1991-11-26 Baxter International Inc. Bioprosthetic ligament
US4996154A (en) 1989-05-04 1991-02-26 Millipore Corporation Method for growing cellular tissue
WO1991001720A1 (en) 1989-08-07 1991-02-21 Herman Wade Schlameus Composition and method of promoting hard tissue healing
EP0526550B1 (en) 1990-04-24 1997-12-29 EISENBERG, Mark Composite living skin equivalents
US5231169A (en) * 1990-10-17 1993-07-27 Norian Corporation Mineralized collagen
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5326357A (en) 1992-03-18 1994-07-05 Mount Sinai Hospital Corporation Reconstituted cartridge tissue
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5656450A (en) * 1994-05-27 1997-08-12 Board Of Regents, The University Of Texas System Activation of latent transforming growth factor β by matrix vesicles
US5716413A (en) 1995-10-11 1998-02-10 Osteobiologics, Inc. Moldable, hand-shapable biodegradable implant material
AU7274696A (en) 1995-11-06 1997-05-29 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue

Also Published As

Publication number Publication date
EP0862616A1 (en) 1998-09-09
EP0862616B1 (en) 2008-07-30
DE69637619D1 (en) 2008-09-11
JP2006129874A (en) 2006-05-25
JP2008271977A (en) 2008-11-13
WO1997017430A1 (en) 1997-05-15
ATE402994T1 (en) 2008-08-15
JP2002515731A (en) 2002-05-28
US6464729B1 (en) 2002-10-15
AU7274696A (en) 1997-05-29

Similar Documents

Publication Publication Date Title
CA2236807A1 (en) Reconstituted mineralized cartilage tissue
US20100068241A1 (en) Reconstituted mineralized cartilage tissue
JP2858782B2 (en) Production of articular cartilage and bone regenerating composition, skeletal tissue transplant, and method of regenerating skeletal tissue
US5226914A (en) Method for treating connective tissue disorders
US5197985A (en) Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US8163554B2 (en) Intervertebral disc
US7575743B2 (en) Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells
US6645764B1 (en) Neocartilage and methods of use
US6485723B1 (en) Enhanced submucosal tissue graft constructs
US20050129668A1 (en) Methods, instruments and materials for chondrocyte cell transplantation
US20060195188A1 (en) Biosynthetic composite for osteochondral defect repair
AU2002247044A1 (en) Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells
US20020173806A1 (en) Method for autologous transplantation
EP1109888A1 (en) Enhanced submucosal tissue graft constructs
EP1390471A1 (en) Method for autologous transplantation
ZA200305762B (en) Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells.
AU2002257148A1 (en) Method for autologous transplantation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20121105